Most Shorted Stocks
CMPX is part of our most shorted stocks screen list, indicating it has a high short interest.
COMPASS THERAPEUTICS INC (CMPX) Stock Price & Overview
NASDAQ:CMPX • US20454B1044
Current stock price
5.315 USD
+0.12 (+2.21%)
Last:
The current stock price of CMPX is 5.315 USD. Today CMPX is up by 2.21%. In the past month the price increased by 0.19%. In the past year, price increased by 197.14%.
CMPX Key Statistics
52-Week Range1.665 - 6.88
Current CMPX stock price positioned within its 52-week range.
1-Month Range4.87 - 5.73
Current CMPX stock price positioned within its 1-month range.
- Market Cap
- 957.178M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.43
- Dividend Yield
- N/A
CMPX Stock Performance
Today
+2.21%
1 Week
-5.28%
1 Month
+0.19%
3 Months
-8.77%
Longer-term
6 Months +22.07%
1 Year +197.14%
2 Years +261.11%
3 Years +72.76%
5 Years N/A
10 Years N/A
CMPX Stock Chart
CMPX Stock Screens
CMPX currently appears in the following ChartMill screener lists.
CMPX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CMPX. When comparing the yearly performance of all stocks, CMPX is one of the better performing stocks in the market, outperforming 95.27% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CMPX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CMPX. While CMPX has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CMPX Earnings
Next Earnings DateMay 6, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.09
Revenue Reported
EPS Surprise 2.39%
Revenue Surprise %
CMPX Forecast & Estimates
22 analysts have analysed CMPX and the average price target is 13.77 USD. This implies a price increase of 159.08% is expected in the next year compared to the current price of 5.315.
Analysts
Analysts87.27
Price Target13.77 (159.08%)
EPS Next Y4.9%
Revenue Next YearN/A
CMPX Groups
Sector & Classification
CMPX Financial Highlights
Over the last trailing twelve months CMPX reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS decreased by -16.22% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-66.49M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.28% | ||
| ROE | -33.79% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%18.18%
Sales Q2Q%N/A
EPS 1Y (TTM)-16.22%
Revenue 1Y (TTM)-100%
CMPX Ownership
Ownership
Inst Owners79.19%
Shares180.09M
Float144.80M
Ins Owners6.82%
Short Float %18.04%
Short Ratio12.01
CMPX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 365.196B | ||
| AMGN | AMGEN INC | 15.36 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.9 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.64 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.14 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.24 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 11.19 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.84 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.6 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CMPX
Company Profile
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2020-11-13. The firm is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Company Info
IPO: 2020-11-13
COMPASS THERAPEUTICS INC
80 Guest Street
Boston MASSACHUSETTS US
Employees: 39
Phone: 13026587581
COMPASS THERAPEUTICS INC / CMPX FAQ
What does CMPX do?
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2020-11-13. The firm is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Can you provide the latest stock price for COMPASS THERAPEUTICS INC?
The current stock price of CMPX is 5.315 USD. The price increased by 2.21% in the last trading session.
Does COMPASS THERAPEUTICS INC pay dividends?
CMPX does not pay a dividend.
What is the ChartMill rating of COMPASS THERAPEUTICS INC stock?
CMPX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the next earnings date for CMPX stock?
COMPASS THERAPEUTICS INC (CMPX) will report earnings on 2026-05-06.
Who owns COMPASS THERAPEUTICS INC?
You can find the ownership structure of COMPASS THERAPEUTICS INC (CMPX) on the Ownership tab.